Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Study of Two Adagrasib Dosing Regimens in Previously Treated KRAS G12C-Mutated NSCLC
jRCT2051250087Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate. Started Jul 2025; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250087.